Whole-Brain *N*-Acetylaspartate Concentration Is Preserved during Mild Hypercapnia Challenge

S. Chawla, Y. Ge, H. Lu, O. Marshall, M.S. Davitz, G. Fatterpekar, B.J. Soher, and O. Gonen

ABSTRACT

BACKGROUND AND PURPOSE: Although NAA is often used as a marker of neuronal health and integrity in neurologic disorders, its normal response to physiologic challenge is not well-established and its changes are almost always attributed exclusively to brain pathology. The purpose of this study was to test the hypothesis that the neuronal cell marker NAA, often used to assess neuronal health and integrity in neurologic disorders, is not confounded by (possibly transient) physiologic changes. Therefore, its decline, when observed by using ¹H-MR spectroscopy, can almost always be attributed exclusively to brain pathology.

MATERIALS AND METHODS: Twelve healthy young male adults underwent a transient hypercapnia challenge (breathing 5% CO₂ air mixture), a potent vasodilator known to cause a substantial increase in CBF and venous oxygenation. We evaluated their whole-brain NAA by using nonlocalizing proton MR spectroscopy, venous oxygenation with T2-relaxation under spin-tagging MR imaging, CBF with pseudocontinuous arterial spin-labeling, and the cerebral metabolic rate of oxygen, during normocapnia (breathing room air) and hypercapnia.

RESULTS: There was insignificant whole-brain NAA change ($P = .88$) from normocapnia to hypercapnia and back to normocapnia in this cohort, as opposed to highly significant increases: $28.0 \pm 10.3\%$ in venous oxygenation and $49.7 \pm 16.6\%$ in global CBF ($P < 10^{-4}$); and a $6.4 \pm 10.9\%$ decrease in the global cerebral metabolic rate of oxygen ($P = .04$).

CONCLUSIONS: Stable whole-brain NAA during normocapnia and hypercapnia, despite significant global CBF and cerebral metabolic rate of oxygen changes, supports the hypothesis that global NAA changes are insensitive to transient physiology. Therefore, when observed, they most likely reflect underlying pathology resulting from neuronal cell integrity/viability changes, instead of a response to physiologic changes.

ABBREVIATIONS: CMRO₂ = cerebral metabolic rate of oxygen consumption; pCASL = pseudocontinuous arterial spin-labeling; TRUST = T2-relaxation under spin-tagging; WBNA = whole-brain NAA; Yv = venous oxygenation

Proton MR spectroscopy (¹H-MR spectroscopy) allows noninvasive quantitative in vivo assessment of brain metabolites.^{1,2} The most prominent metabolite in water-suppressed ¹H-MR spectroscopy is the amino acid derivative NAA, synthesized in neuronal mitochondria from acetyl coenzyme A and L-aspartate

by a membrane-bound enzyme.³ Although its precise function is still not fully known, possible roles include lipogenesis in myelination, ion balance, neuromodulation, and neuronal mitochondria energy metabolism.⁴ Because it is almost exclusive to neurons and their processes (<10% contribution from glia and extracellular fluid),⁵ NAA is considered a putative marker of their integrity.^{4,6} Indeed, with the exception of Canavan disease,⁷ nearly all brain pathologies show local or global NAA decline due to degeneration or metabolic impairment.^{2,6,8}

Use of NAA as a marker of neuronal health, however, involves 2 implicit assumptions: 1) its concentration is insensitive to (possible) transient physiologic changes of normal physiologic fluctuation; and 2) detectable changes must, therefore, reflect only un-

Received February 10, 2015; accepted after revision April 1.

From the Department of Radiology (S.C., Y.G., O.M., M.S.D., G.F., O.G.), Center for Advanced Imaging Innovation and Research and Bernard and Irene Schwartz Center for Biomedical Imaging, New York University School of Medicine, New York, New York; The Russell H. Morgan Department of Radiology and Radiological Science (H.L.), Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Radiology (B.J.S.), Center for Advanced MR Development, Duke University Medical Center, Durham, North Carolina.

This work was supported by National Institutes of Health grants NS076588, NS029029-S1, MH084021, NS067015, AG042753, EB01015 and EB008387 and by the Center for Advanced Imaging Innovation and Research (www.cai2r.net), a National Institute of Biomedical Imaging and Bioengineering Biomedical Technology Resource Center: P41 EB017183.

Please address correspondence to Yulin Ge, MD, and Oded Gonen, PhD, Department of Radiology, Center for Advanced Imaging Innovation and Research and

Bernard and Irene Schwartz Center for Biomedical Imaging, NY University School of Medicine, 660 First Ave, 4th floor, NY, NY 10016; e-mail: yulin.ge@nyumc.org; oded.gonen@nyumc.org

Indicates open access to non-subscribers at www.ajnr.org

<http://dx.doi.org/10.3174/ajnr.A4424>

FIG 1. Automated spectral fitting of the pre- (left), during- (center), and posthypercapnia (right) WBNAAs from 1 subject, all on the same intensity and chemical shift (parts per million [ppm]) scales. *Top, A*, Whole-head ^1H -spectrum (thin black line), estimated baseline (dashed line), and fitted (metabolites + baseline) estimate (thick gray line). *Bottom: B*, Residual signals (raw-fitted data). Note: 1) The similarity of the pre-, during, and posthypercapnia spectra, suggesting a minimal effect of this physiologic challenge on the brain NAA; 2) the quality of the fit on A; and 3) the consequent vanishing residuals in B; and 4) although other metabolites are also visible in the spectrum, only NAA is implicitly localized by its biochemistry to just the brain.

derlying pathology. Although stable NAA levels are reported in response to aerobic exercise,⁹ verbal memory performance,¹⁰ and caffeine ingestion¹¹ and alcohol consumption in healthy humans,¹² and prolonged hypoglycemia in the rat brain,¹³ these 2 assumptions are made for expediency because little is known of the response of NAA to other physiologic challenges.^{6,14}

Given its utility as a neuronal marker, our goal in the present study was to test the hypothesis that the global NAA concentration remains stable even under a substantial physiologic challenge that leads to otherwise easily detectable changes in other MR imaging metrics. We chose the mild hypercapnia paradigm (5% CO_2 by volume in inspired air) to test it for 5 reasons: First, it is a potent vasodilator, known to cause a dramatic, easily measurable 20%–50% increase in CBF.^{15,16} Second, it has quick (~ 1 minute) onset and washout, making both states accessible within 1 MR imaging session. Third, its blood level can be reliably and instantly monitored by capnography. Fourth, animal studies have shown that NAA synthesis can be disrupted when O_2 consumption and adenosine triphosphate production are decreased by inhibitors of the mitochondrial respiratory chain.¹⁷ Finally, it is also clinically and practically relevant for NAA quantification because patients with neurologic conditions often have irregular respiratory patterns during scans, which may lead to higher blood partial arterial CO_2 pressure.

To test the hypothesis and to quantify the hereto unknown effects of hypercapnia on NAA, we used whole-brain NAA (WBNAAs) nonlocalizing ^1H -MR spectroscopy^{18,19} and compared its changes with those observed with other MR imaging modalities: T2-relaxation under spin-tagging (TRUST) and pseudocontinuous arterial spin-labeling (pCASL) perfusion MR imaging, to quantify variations in venous oxygenation (Yv), CBF, and the cerebral metabolic rate of oxygen consumption (CMRO_2) in normocapnia (breathing room air) and during transient hypercapnia in healthy young adults.

MATERIALS AND METHODS

Participants

Twelve healthy young men (30.5 ± 9.2 years of age; range, 23–48 years) were prospectively enrolled in this study. Only young men were chosen to remove possible age and sex effects on the acquired metrics. None were smokers or had a history of asthma or neurologic or psychological disorders before the scan, and all had “unremarkable MR imaging” findings determined by a neuroradiologist afterward. All were also instructed to not drink coffee for 6 hours before the study. All participants provided institutional review board–approved written informed consent.

^1H -MR Spectroscopy WBNAAs

The WBNAAs ^1H -MR spectroscopy was acquired in a 3T whole-body MR imaging scanner (Tim Trio; Siemens, Erlangen, Germany) by using a circularly polarized transmit-receive head coil (TEM3000; MR Instruments, Minneapolis, Minnesota). After optimizing the magnetic field over the whole head with our proton chemical shift imaging–based automatic procedure,²⁰ we obtained the WBNAAs with a nonlocalizing nonecho ^1H -MR spectroscopy sequence^{18,19}: TR/TE/TI = 10000/5/940 ms, 16 averages, 90° flip angle, ± 1 KHz acquisition bandwidth. The use of $\text{TR} \gg \text{T}_1$ and $\text{TE} \approx 0$ ensured insensitivity to (unknown) T_1 and T_2 variations, and whole-head volume of interest facilitates both a short, 2 minutes and 40 seconds, acquisition and an excellent signal-to-noise ratio, as seen in Fig 1.

MR Imaging Methods

All MR imaging examinations were performed in the same scanner by using a 12-channel array head coil. Clinical standard T1-weighted high-resolution (1 mm^3) 3D-MPRAGE and T2-weighted MR imaging were performed on every subject to exclude brain abnormalities. Subsequently, 2 advanced quantitative MR imaging sequences, TRUST and pCASL, were applied to estimate global Yv and CBF, from which the CMRO_2 was obtained.

TRUST uses spin-labeling to isolate pure venous blood signals and measures T2 value, which is converted to an O_2 saturation fraction (Yv) with a calibration plot.²¹ TRUST MR imaging was performed with single-section EPI intersecting the lower superior sagittal sinus. Because this sinus drains most of the cerebrum, TRUST-obtained Yv is essentially a global metric. Acquisition parameters were $3.6 \times 3.6 \times 5 \text{ mm}^3$ voxels; TR = 8000 ms; TI = 1200 ms; 10-ms Carr Purcell Meiboom Gill sequence; 4 effective TEs = 0, 40, 80, and 160 ms; and 4:48-minute total acquisition time. The labeling slab was 50-mm-thick with a 25-mm gap between it and the imaging section.

CBF was obtained with perfusion imaging, by using the multisection pseudocontinuous arterial spin-labeling sequence covering the entire brain. This sequence was recently recommended by a white paper for clinical perfusion MR imaging.²² It is based

on a single-shot gradient-echo EPI: TR/TE = 3900/17 ms; labeling duration = 1470 ms; postlabeling delay = 1230 ms; section thickness = 5 mm; 24 axial sections; $22 \times 22 \text{ cm}^2$ FOV; 64×64 matrix ($3.4 \times 3.4 \times 5 \text{ mm}^3$ voxels); integrated parallel acquisition technique factor of 2 and 52 measurements (26 pairs of label and control images) for a 3 minute and 35 second acquisition time. Arterial spin-labeling was performed 97 mm below the center-of-imaging volume approximately perpendicular to the internal carotid and vertebral arteries.

EXPERIMENTAL PROCEDURES

The participants underwent WBNA, TRUST, and pCASL MR imaging under normocapnia and hypercapnia (5% CO₂, 21% O₂, and 74% N₂ mixture from a Douglas bag). Each was fitted with a nose clip, and the gas from each of the 2 sources was delivered through a 2-way nonbreathing valve and mouthpiece combination (2600 series; Hans Rudolph, Shawnee, Kansas). Their end-tidal CO₂ values, the CO₂ concentration levels in the lung that approximate those in arterial blood (ie, partial arterial CO₂ pressure), were recorded throughout the experiment at 2-second intervals with an MR imaging-compatible 9500 Multigas Monitor (Medrad, Indianola, Pennsylvania). The averaged end-tidal CO₂ during each room air and hypercapnia scan was then calculated and reported.

The experimental paradigm comprised ¹H-MR spectroscopy WBNA (2:40 minutes), pCASL (3:35 minutes), and TRUST (4:48 minutes) during normocapnia then hypercapnia and additional posthypercapnia normocapnia for WBNA only, to test whether hypercapnia-induced WBNA change, if present, recovers. The time interval needed to reach a new steady-state after switching the gas from one condition to another was monitored in each subject and usually took less <1 minute.

Data Processing and Analyses

WBNA. Data processing and spectral fitting were performed by using the VeSPA software package (<https://scion.duhs.duke.edu/vespa/project>).²³ The VeSPA-Analysis application was extracted from the ¹H-MR spectroscopy data from the MR imaging scanner file format and applied a standard set of preset processing and spectral fitting parameters: Even time-signals were subtracted from the odd ones, the pairs were summed, and the spectral data were fitted parametrically by using the automated algorithm described previously.^{19,24,25} The metabolite basis set for the parametric fit (synthesized with the VeSPA-Simulation application by using the radiofrequency pulses and timings from the actual WBNA sequence) included the total-NAA (NAA + NAA-glutamate at a 7:1 ratio), glutamate, glutamine, total Cho, total Cr, and mIns. The latter 5 were included in the parametric model as known “nuisance signals” to simplify the use of wavelet filtering to account for nonparametric residual baseline signals. The inter- and intrasubject WBNA signal area variability with this approach is $\pm 12\%$ and $\pm 7\%$.¹⁹ Because only within-subject changes from normocapnia to hypercapnia were sought for comparison, only percentage variations in WBNA levels are reported in this study.

pCASL. The difference between the label and control images was

calculated, and the CBF map produced normocapnia and hypercapnia by using a previously described perfusion kinetic model^{22,26}:

1) $\text{CBF (ml/100 g/minute)}$

$$= \frac{60 \times 100 \times \Delta M \times \lambda}{2\alpha \times M_0 \times T_1 \times (e^{-w/T_1} - e^{-(w+\tau)/T_1})}$$

where ΔM is the difference signal between control and labeling states; $\lambda = 0.9 \text{ mL/g}$ is the blood/tissue water partition coefficient; $\alpha = 0.86$ is the labeling efficiency of pCASL at $3T^{22,26}$; M_0 is the equilibrium magnetization of brain tissue during the nonlabeled condition, after accounting for blood T₁ (1600 ms) at $3T^{27}$; w is the postlabeling delay, which is different for individual sections ($1.23\text{-second} + \text{section acquisition delay}$)²⁷; and τ is the labeling duration (1.47 seconds in our data). To obtain the average CBF map for each breathing condition, we transformed each individual's images into the Montreal Neurological Institute template of 152 space-masking brain-only regions and spatially smoothed them by using a Gaussian kernel (8-mm full width at half maximum). GM CBF values were computed by overlaying the tissue mask (defined as 70% probability of being GM) on the normalized CBF maps. Global CBF was also computed by overlaying the whole-brain mask, excluding the CSF, on the normalized CBF maps, and it was obtained an averaged CBF over all sections including both GM and WM.

TRUST and CMRO₂. For Y_v estimates, the TRUST data were processed by using in-house Matlab (MathWorks, Natick, Massachusetts) scripts based on a previously described algorithm.²¹ Briefly, these images were motion-corrected and pair-wise subtracted (control-labeled images), resulting in a pure blood signal in the lower superior sagittal sinus. The averaged venous blood signal for each effective TE was fitted to a monoexponential model to obtain a blood T₂, which was converted to Y_v via a calibration plot established with in vitro blood by using subject-specific hematocrit values. CMRO₂ (micromole O₂/100 g tissue/minute) was then estimated by using the Kety-Schmidt method,²⁸

2) $\text{CMRO}_2 = \text{CBF} \times (Y_a - Y_v) \times C_a$,

where CBF is expressed in milliliters/100 g/minute and is obtained from the pCASL data; Y_a is the percentage of arterial oxygenation obtained by using finger pulse oximetry; and C_a the amount of oxygen a unit volume of blood can carry, assumed to be $856.2 \mu\text{mol}/100 \text{ mL}$. Note that because CBF and Y_v are global metrics, so is the CMRO₂ from either the GM or whole brain.

Statistical Analyses

Kolmogorov-Smirnov tests were used to determine data distributions. Paired-samples *t* tests were performed to look for differences between hypercapnia and normocapnia in WBNA, Y_v, global CBF, GM CBF, global CMRO₂, and GM CMRO₂. $P < .05$ was considered significant. All analyses were performed with SPSS for Windows, Version 15.0 (IBM, Armonk, New York).

RESULTS

The end-tidal CO₂ and MR imaging/MR spectroscopy metrics for normocapnia and hypercapnia and their comparisons are sum-

Summary of ETCO₂ and MRI metrics (mean) for normocapnia and hypercapnia

MRI/MRS and Measures	Normocapnia	Hypercapnia	P Value
¹ H-MRS ^a			
ETCO ₂ (mm Hg)	44.40 ± 4.1	52.9 ± 2.4	<10 ⁻⁴
WBNAa (arb. unit)	177.9 ± 40.5	178.8 ± 32.3	.88
pCASL MRI			
ETCO ₂ (mm Hg)	40.6 ± 4.9	49.4 ± 3.9	<10 ⁻⁴
CBF (mL/100 g/min)	33.9 ± 6.3	50.2 ± 6.9	<10 ⁻⁴
TRUST MRI			
ETCO ₂ (mm Hg)	43.3 ± 4.7	52.5 ± 2.9	<10 ⁻⁴
Yv (%)	56.4 ± 5.6	71.9 ± 4.8	<10 ⁻⁴
TRUST and pCASL			
CMRO ₂ (μmol/100 g/min)	120.0 ± 23.9	111.2 ± 18.9	.04

Note:—Arb. indicates arbitrary; ETCO₂, end-tidal carbon dioxide.

^aWBNAa values measured with ¹H-MRS of the posthypercapnic condition (the second normocapnia) are listed in the main text.

FIG 2. A, Boxplots showing the first, second (median), and third quartiles (box) and $\pm 95\%$ (whiskers) of the WBNAa distributions at normocapnia (white), hypercapnia (hatched), and posthypercapnia (cross-hatched). Note the insignificant WBNAa changes ($P = .676$). B, Boxplots show the percentage of NAA change from baseline normocapnia distribution of the 12 subjects. Note the $\sim 0\%$ change from normocapnia (preHC) to hypercapnia (HC) (hatched) and from the former to the posthypercapnia (postHC) normocapnia (cross-hatched), underscoring the negligible NAA change as a response to the physiologic CO₂ challenge. Arb indicates arbitrary.

marized in the Table. As expected, the end-tidal CO₂ increased significantly from normocapnia to hypercapnia: 44.4 ± 4.1 to 52.9 ± 2.4 mm Hg for WBNAa, 40.6 ± 4.9 to 49.4 ± 3.9 mm Hg for pCASL, and 43.3 ± 4.7 to 52.5 ± 2.9 mm Hg for TRUST ($P < 10^{-4}$ for all). The average range of end-tidal CO₂ changes during the 3 scans was tight: between 8 and 9 mm Hg.

WBNAa

Our automatic shimming yielded a 27 ± 4 Hz whole-head water line width in <5 minutes. Sample whole-head ¹H-MR spectroscopy during normocapnia, hypercapnia, and subsequent normocapnia are shown in Fig 1, and their distribution for all 12 subjects is shown in Fig 2A. On the basis of paired-samples *t* tests, there

were insignificant $2.7 \pm 15.1\%$ changes from normocapnia to hypercapnia and $0.6 \pm 18.2\%$ from pre- to posthypercapnia normocapnia ($P = .88$), as shown in Fig 2B.

pCASL

The average global CBF maps during normocapnia and hypercapnia from all 12 subjects are shown in Fig 3. There was a highly significant $49.7 \pm 16.6\%$ increase in global CBF from 33.9 ± 6.3 mL/100 g/min in normocapnia to 50.2 ± 6.9 mL/100 g/min in hypercapnia ($P < 10^{-4}$), as shown in Fig 4A. Similarly, GM CBF increased a significant 40.0% from 45.3 ± 7.4 mL/100 g/min at normocapnia to 63.0 ± 8.6 mL/100 g/min at hypercapnia ($P < 10^{-4}$).

TRUST and CMRO₂

The lower superior sagittal sinus blood T2 increased from 54.6 ± 8.9 ms at normocapnia to 85.0 ± 11.8 ms at hypercapnia, and the corresponding Yv increased from $56.4 \pm 5.6\%$ to $71.9 \pm 4.8\%$ ($P < 10^{-4}$ for both). The global CMRO₂ declined a significant $6.4 \pm 10.9\%$: from 120.0 ± 23.9 μmol/100 g/min at normocapnia to 111.2 ± 18.9 μmol/100 g/min at hypercapnia ($P = .04$), as shown in Fig 4B. GM CMRO₂ also decreased a significant $11.3 \pm 11.6\%$, from 162.2 ± 40.1 μmol/100 g/min at normocapnia to 141.2 ± 24.7 μmol/100 g/min at hypercapnia ($P = .01$).

DISCUSSION

The findings substantiate the hypothesis that WBNAa is insensitive to a physiologic challenge that otherwise leads to significant variations in Yv, CBF, and CMRO₂. This finding suggests that neurons tolerate hypercapnia with unaltered structural or functional integrity. Consequently, blood partial arterial CO₂ pressure fluctuations (eg, due to irregular respiratory patterns during ¹H-MR spectroscopy scans) will likely have minimal effect on the NAA concentrations. Insensitivity to such an intense challenge suggests that NAA changes, when observed, most likely represent disease pathology and not physiology.

Hypercapnia is increasingly used to study cerebrovascular reactivity in clinical populations,^{29,30} as well as to calibrate blood oxygen level-dependent signal.³¹ Its well-known effect is a remarkable vasodilation leading to substantial CBF increase. Although the precise vasodilatory mechanism of CO₂ in humans is not well-known, it is believed that it activates potassium-adenosine triphosphate channels in vascular smooth muscle, causing dilation.³² However, the effect of CO₂ inhalation on neural activity

Normocapnia

FIG 3. Average ($n = 12$) global CBF maps for 7 representative brain sections. Note the easily visible, $\sim 50\%$ increase ($P < 10^{-4}$) in CBF from normocapnia to hypercapnia.

FIG 4. Boxplots of the distributions of global CBF (A) and $CMRO_2$ (B) at normocapnia (white) and hypercapnia (hatched). Note the significant ($P < 10^{-4}$) $\sim 47\%$ increases in global CBF and the 6.4% ($P = .04$) decrease in global $CMRO_2$ from normocapnia to hypercapnia.

or $CMRO_2$ is unclear, and its results are controversial. Earlier studies showed constant $CMRO_2$ at hypercapnia,²⁸ whereas others found that it decreased,^{33,34} as in this study, or even increased.³⁵ These findings may be due to different methodologies (eg, strength and duration of CO_2 stimulus), use of anesthetic agents, and species studied. The large increase in CBF with mild reduction in $CMRO_2$ under hypercapnia observed here suggests uncoupling of these metrics due to increased partial pressure of

carbon dioxide acting primarily on adenosine receptors to dilate blood vessels.

It is nevertheless intriguing why, despite significant CBF increase and likely neuronal activity ($CMRO_2$) decline, NAA levels remains constant, because it is known that under normal conditions, brain NAA level fluctuations are expected to link neuronal-to-mitochondrial activity.³ Indeed, animal studies have shown that NAA synthesis can be disrupted when O_2 consumption and adenosine triphosphate production are decreased by inhibitors of the mitochondrial respiratory chain,¹⁷ and a marked reduction in mitochondrial respiratory activities was observed in rodents exposed to intermittent hypoxia/hypercapnia for several days.³⁶ Together, these studies support the notion that relatively severe prolonged hypercapnia may have a detrimental effect on neuronal metabolism, leading to cell death, whereas in this study, the challenge was mild and its duration was short.

The above conjecture is also supported by the observed lack of NAA changes in the few other 1H -MR spectroscopy studies involving short physiologic challenges (eg, in response to aerobic exercise,⁹ verbal memory performance,¹⁰ and caffeine ingestion¹¹ in healthy humans, and alcohol consumption¹² and prolonged hypoglycemia in the rat brain¹³) consistent with neuronal and mitochondrial integrity preservation. Furthermore, because NAA accounts only for a very small fraction, $<0.05\%$, of the overall glucose metabolism, and its turnover rate is slow,⁸ its concentration is also unaffected by extended hypoglycemia.¹³ These findings lend further support to the notion that NAA is not an energy-buffering store (hence, requiring quick response) for neuronal activity in normal tasks.¹³ At lower partial arterial CO_2 pressure, a recent study found that induced acidosis plays a role in maintaining mitochondrial function, regulating its metabolic pathway to preserve adenosine triphosphate production.³⁷ We believe that a relatively slower adaptive NAA metabolism may account for its preserved level despite a $CMRO_2$ decrease, suggesting that NAA is a cellular integrity index, (ie, sensitive to the number of neurons per unit volume and their overall viability), while $CMRO_2$ is a flux measure (ie, sensitive to instantaneous physiologic changes).

In the current study, we used WBNA to assess the global variation in NAA during hypercapnia because of the global effect

of CO₂, which can be detected more reliably than single- or multivoxel MR spectroscopy methods, in particular when such an effect on NAA change is considered consistent among different regions. Our Yv and CMRO₂ measures are also global indices, by which WBNA results are expected to be more comparable with CMRO₂ changes at the similar global level. Because most of the neurodegenerative diseases such as Alzheimer disease, amyotrophic lateral sclerosis, multiple sclerosis, and frontotemporal dementia are widespread in nature and involve more extended regions than previously understood, it is also more sensible to assess global variation in NAA levels following a physiologic challenge. Using a single-voxel technique, previous studies have reported no significant regional NAA change with other physiologic challenges, which is consistent with our whole-brain NAA findings.^{9–12}

Admittedly, this study also has several limitations: First, the hypercapnia challenge lasted only several minutes. However, it is known that acute challenges (eg, partial hypoxia in stroke,³⁸) may lead to NAA decline in a matter of minutes, suggesting that the duration of our paradigm may be appropriate to affect a change if there was one. Higher than normal partial arterial CO₂ pressure is common in subjects with chronic respiratory disorders, which may exist as comorbidities in patients with neurologic disorders during ¹H-MR spectroscopy. Our study, by its design, excludes the effect on brain NAA from both prolonged hypoxia and elevated partial arterial CO₂ pressure. Second, we restricted our study to young adult men, to remove (possible) age and sex differences in the metrics compared. However, the WBNA insensitivity to hypercapnia in this cohort suggests that similar findings are expected in a more age- and sex-diverse group. Third, the whole-brain CBF values are slightly lower than those commonly reported because WM CBF is usually underestimated with arterial spin-labeling sequences. Because this study compared CBF between the 2 breathing conditions within a subject, however, its underestimation is expected to be similar between them.

CONCLUSIONS

Our study suggests that the NAA concentration is insensitive to even intensive transient physiologic challenges absent underlying pathology that affects the integrity or viability of these cells, meeting the requirement of a marker of neuronal cell integrity. The finding with this specific challenge paradigm is particularly germane to better understanding of NAA changes, specifically to NAA quantification when the subjects have an irregular breathing pattern during ¹H-MRS acquisition, in which elevated partial arterial CO₂ pressure can be seen.

Disclosures: Yulin Ge—RELATED: Grant: National Institutes of Health,* Comments: This work was supported by National Institutes of Health grants NS076588, NS029029-S1, MH084021, NS067015, AG042753, EB01015, and EB008387 and by the Center for Advanced Imaging Innovation and Research (www.cai2r.net), a National Institute of Biomedical Imaging and Bioengineering Biomedical Technology Resource Center: P41 EB017183. *Money paid to the institution.

REFERENCES

- Oz G, Alger JR, Barker PB, et al; MRS Consensus Group. **Clinical proton MR spectroscopy in central nervous system disorders.** *Radiology* 2014;270:658–79 [CrossRef Medline](#)
- Mountford CE, Stanwell P, Lin A, et al. **Neurospectroscopy: the past, present and future.** *Chem Rev* 2010;110:3060–86 [CrossRef Medline](#)
- Moffett JR, Ross B, Arun P, et al. **N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology.** *Prog Neurobiol* 2007;81:89–131 [CrossRef Medline](#)
- Baslow MH. **N-acetylaspartate in the vertebrate brain: metabolism and function.** *Neurochem Res* 2003;28:941–53 [CrossRef Medline](#)
- Taylor DL, Davies SE, Obrenovitch TP, et al. **Extracellular N-acetylaspartate in the rat brain: in vivo determination of basal levels and changes evoked by high K⁺.** *J Neurochem* 1994;62:2349–55 [Medline](#)
- Benarroch EE. **N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance.** *Neurology* 2008;70:1353–57 [CrossRef Medline](#)
- Baslow MH, Guilfoyle DN. **Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions.** *Biochimie* 2013;95:946–56 [CrossRef Medline](#)
- Choi IY, Gruetter R. **Dynamic or inert metabolism? Turnover of N-acetyl aspartate and glutathione from D-[1–13C]glucose in the rat brain in vivo.** *J Neurochem* 2004;91:778–87 [CrossRef Medline](#)
- Caglar E, Sabuncuoğlu H, Keskin T, et al. **In vivo human brain biochemistry after aerobic exercise: preliminary report on functional magnetic resonance spectroscopy.** *Surg Neurol* 2005;64 (suppl 2): S53–56; discussion S56–67 [Medline](#)
- Hagino H, Suzuki M, Mori K, et al. **Proton magnetic resonance spectroscopy of the inferior frontal gyrus and thalamus and its relationship to verbal learning task performance in patients with schizophrenia: a preliminary report.** *Psychiatry Clin Neurosci* 2002; 56:499–507 [CrossRef Medline](#)
- Dager SR, Layton ME, Strauss W, et al. **Human brain metabolic response to caffeine and the effects of tolerance.** *Am J Psychiatry* 1999; 156:229–37 [Medline](#)
- Liu H, Zheng W, Yan G, et al. **Acute ethanol-induced changes in edema and metabolite concentrations in rat brain.** *Biomed Res Int* 2014;2014:351903 [CrossRef Medline](#)
- Rao R, Ennis K, Long JD, et al. **Neurochemical changes in the developing rat hippocampus during prolonged hypoglycemia.** *J Neurochem* 2010;114:728–38 [CrossRef Medline](#)
- Rigotti DJ, Inglese M, Gonen O. **Whole-brain N-acetylaspartate as a surrogate marker of neuronal damage in diffuse neurologic disorders.** *AJNR Am J Neuroradiol* 2007;28:1843–9 [CrossRef Medline](#)
- Marshall O, Lu H, Briset JC, et al. **Impaired cerebrovascular reactivity in multiple sclerosis.** *JAMA Neurol* 2014;71:1275–81 [CrossRef Medline](#)
- Pollock JM, Deibler AR, Whitlow CT, et al. **Hypercapnia-induced cerebral hyperperfusion: an underrecognized clinical entity.** *AJNR Am J Neuroradiol* 2009;30:378–85 [CrossRef Medline](#)
- Bates TE, Strangward M, Keelan J, et al. **Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo.** *Neuroreport* 1996;7:1397–400 [CrossRef Medline](#)
- Gonen O, Viswanathan AK, Catalaa I, et al. **Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy.** *Magn Reson Med* 1998;40:684–89 [CrossRef Medline](#)
- Soher BJ, Wu WE, Tal A, et al. **Automated whole-brain N-acetylaspartate proton MRS quantification.** *NMR Biomed* 2014;27:1275–84 [CrossRef Medline](#)
- Hu J, Javadi T, Arias-Mendoza F, et al. **A fast, reliable, automatic shimming procedure using 1H chemical-shift-imaging spectroscopy.** *J Magn Reson B* 1995;108:213–19 [CrossRef Medline](#)
- Lu H, Ge Y. **Quantitative evaluation of oxygenation in venous vessels using T2-relaxation-under-spin-tagging MRI.** *Magn Reson Med* 2008;60:357–63 [CrossRef Medline](#)
- Wu WC, Fernández-Seara M, Detre JA, et al. **A theoretical and experimental investigation of the tagging efficiency of pseudocontinuous arterial spin labeling.** *Magn Reson Med* 2007;58:1020–27 [CrossRef Medline](#)
- Soher BJ, Semanchuk P, Todd D, et al. **Vespa: Integrated applica-**

- tions for RF pulse design, spectral simulation and MRS data analysis. In: *Proceedings of the Annual Meeting of the International Society for Magnetic Resonance in Medicine*, Montreal, Quebec, Canada. May 6–13, 2011:1410
24. Young K, Soher BJ, Maudsley AA. **Automated spectral analysis II: application of wavelet shrinkage for characterization of non-parameterized signals.** *Magn Reson Med* 1998;40:816–21 [CrossRef Medline](#)
 25. Soher BJ, Young K, Govindaraju V, et al. **Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging.** *Magn Reson Med* 1998;40:822–31 [CrossRef Medline](#)
 26. Aslan S, Xu F, Wang PL, et al. **Estimation of labeling efficiency in pseudocontinuous arterial spin labeling.** *Magn Reson Med* 2010;63:765–71 [CrossRef Medline](#)
 27. Lu H, Clingman C, Golay X, et al. **Determining the longitudinal relaxation time (T1) of blood at 3.0 Tesla.** *Magn Reson Med* 2004;52:679–82 [CrossRef Medline](#)
 28. Kety SS, Schmidt CF. **The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values.** *J Clin Invest* 1948;27:476–83 [CrossRef Medline](#)
 29. Yezhuvath US, Uh J, Cheng Y, et al. **Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's disease.** *Neurobiol Aging* 2012;33:75–82 [CrossRef Medline](#)
 30. Donahue MJ, Strother MK, Hendrikse J. **Novel MRI approaches for assessing cerebral hemodynamics in ischemic cerebrovascular disease.** *Stroke* 2012;43:903–15 [CrossRef Medline](#)
 31. Mark CI, Slessarev M, Ito S, et al. **Precise control of end-tidal carbon dioxide and oxygen improves BOLD and ASL cerebrovascular reactivity measures.** *Magn Reson Med* 2010;64:749–56 [CrossRef Medline](#)
 32. Wang X, Wu J, Li L, et al. **Hypercapnic acidosis activates KATP channels in vascular smooth muscles.** *Circ Res* 2003;92:1225–32 [CrossRef Medline](#)
 33. Sicard KM, Duong TQ. **Effects of hypoxia, hyperoxia, and hypercapnia on baseline and stimulus-evoked BOLD, CBF, and CMRO2 in spontaneously breathing animals.** *Neuroimage* 2005;25:850–58 [CrossRef Medline](#)
 34. Xu F, Uh J, Brier MR, et al. **The influence of carbon dioxide on brain activity and metabolism in conscious humans.** *J Cereb Blood Flow Metab* 2011;31:58–67 [CrossRef Medline](#)
 35. Jones M, Berwick J, Hewson-Stoate N, et al. **The effect of hypercapnia on the neural and hemodynamic responses to somatosensory stimulation.** *Neuroimage* 2005;27:609–23 [CrossRef Medline](#)
 36. Douglas RM, Ryu J, Kanaan A, et al. **Neuronal death during combined intermittent hypoxia/hypercapnia is due to mitochondrial dysfunction.** *Am J Physiol Cell Physiol* 2010;298:C1594–602 [CrossRef Medline](#)
 37. Khacho M, Tarabay M, Patten D, et al. **Acidosis overrides oxygen deprivation to maintain mitochondrial function and cell survival.** *Nat Commun* 2014;5:3550 [Medline](#)
 38. Barker PB, Gillard JH, van Zijl PC, et al. **Acute stroke: evaluation with serial proton MR spectroscopic imaging.** *Radiology* 1994;192:723–32 [CrossRef Medline](#)